Tomas Navratil has sold GKOS and made no open-market buys since Mar 2026

Tomas Navratil, Ph.D., is the Chief Development Officer of Glaukos Corporation (GKOS) and a seasoned leader in ophthalmic drug and medical device research and development.( He has served as chief development officer since April 2022 after initially joining Glaukos in October 2020 as senior vice president of research and development, bringing nearly two decades of experience across clinical development, regulatory affairs, and product innovation for ocular therapies.( In June 2026, as a corporate insider, he executed a Rule 10b5-1 trading plan transaction involving the sale of Glaukos common stock while retaining a significant equity stake in the company.(

Before Glaukos, Navratil held multiple senior leadership roles at Nicox, including general manager of Nicox Ophthalmics, Inc. and executive vice president and global head of R&D for Nicox S.A., and previously served as senior vice president of development at Envisia Therapeutics.( Earlier in his career, he held director-level positions in drug discovery, clinical research and development, and medical affairs at Parion Sciences and Inspire Pharmaceuticals, contributing to numerous clinical programs and regulatory submissions to the U.S. Food and Drug Administration, the European Medicines Agency, and Asia-Pacific regulators.( Navratil has been issued multiple patents and authored publications in ocular and pulmonary drug delivery and product development, and he earned both his B.S. and Ph.D. in chemistry as a Morehead Scholar at the University of North Carolina at Chapel Hill.(

Written by Perplexity from public sources.